Aroa Biosurgery Full Year 2025 Earnings: Revenues Beat Expectations, EPS Lags
Net loss: NZ$3.81m (loss narrowed by 64% from FY 2024).
NZ$0.011 loss per share (improved from NZ$0.031 loss in FY 2024).
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 76%.
Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Biotechs industry in Australia.
Performance of the Australian Biotechs industry.
The company's shares are up 13% from a week ago.
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Aroa Biosurgery's balance sheet and an in-depth analysis of the company's financial position.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Se produjo un error al recuperar la información
Inicia sesión para acceder a tu portafolio
Se produjo un error al recuperar la información
Se produjo un error al recuperar la información
Se produjo un error al recuperar la información
Se produjo un error al recuperar la información
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Australian Unemployment Falls, Supporting Case for RBA Rate Hold
Australia' jobless rate ticked lower and employment rose, signaling the labor market remains tight and reinforcing the Reserve Bank's cautious approach to policy easing. The jobless rate fell to 4.2% in July, from a four-year high of 4.3% the prior month, matching economists' forecasts, data from the Australian Bureau of Statistics showed Thursday. Employment rose by 24,500 driven entirely by full-time roles.
Business Upturn
2 hours ago
- Business Upturn
Nomura reiterates buy on Infosys, sets Rs 1,880 target price after Australian carve-out deal with Telstra
By Markets Desk Published on August 14, 2025, 07:58 IST Nomura has reiterated its buy call on Infosys with a target price of ₹1,880 after the company announced a carve-out deal in Australia with Telstra. Under the agreement, Infosys will acquire a 75% stake and operational control in a newly created entity, while Telstra will retain the remaining 25%. The Indian IT major will pay AUD 233 million for its stake. Nomura estimates the acquisition will add around $70 million to Infosys' revenue in FY26, contributing approximately 35 basis points to overall growth. The brokerage views the deal as a strategic expansion of Infosys' capabilities and client reach in the Australian market, further strengthening its partnership with Telstra. The brokerage believes the move aligns with Infosys' focus on targeted acquisitions to drive geographic and sectoral growth, and with the company's solid balance sheet, it sees scope for further such transactions to enhance long-term earnings visibility. Disclaimer: The views and recommendations made in this article are those of Nomura. This article does not constitute investment advice. Investors should consult their financial advisors before making any investment decisions. Ahmedabad Plane Crash Markets Desk at
Business Upturn
2 hours ago
- Business Upturn
Morgan Stanley keeps equal-weight on Infosys after JV with Telstra in Australia
By Markets Desk Published on August 14, 2025, 07:57 IST Morgan Stanley has maintained its equal-weight rating on Infosys with a target price of ₹1,700 following the company's announcement of a joint venture with Telstra in Australia. The JV builds on the existing collaboration between the two companies and includes Versent Group, which has a strong client base across government, education, financial services, energy, and utilities sectors. The brokerage said the deal strengthens Infosys' local presence in the Australian market and complements its strategic push in digital transformation services. It added that the price paid for the stake is not considered expensive, and assuming a high single-digit margin profile, the JV is not expected to dilute earnings per share. Morgan Stanley noted that while the transaction is strategically positive, it remains neutral on the stock due to valuation considerations and a balanced risk-reward profile at current levels. Disclaimer: The views and recommendations made in this article are those of Morgan Stanley. This article does not constitute investment advice. Investors should consult their financial advisors before making any investment decisions. Ahmedabad Plane Crash Markets Desk at
